What kind of expertise do you need?

  • Ultimately, commercial success depends on payers and policy makers alike recognizing the value of your product. Its foundation lies in a convincing product value strategy underpinned by scientifically accurate evidence. That’s where we can help. Our multidisciplinary team of experts, in collaboration with professors at top universities, combines state-of-the-art research methods with market-driven strategies from the business, academic, and policy worlds. Together, we serve as your dedicated scientific advisory panel, delivering practical insights to help you take action and present arguments to better inform your audiences.

  • Evidence strategy

    You need a strategy to prove your drug’s value to key stakeholders—payers, integrated delivery networks, clinicians. We begin with quantitative value assessments, then leverage your product’s clinical, economic, and humanistic attributes—aligning with your existing medical and market access strategies:

    • Translating existing data into impactful short-term initiatives and evidence
    • Developing longer-term research protocols and evidence through clinical development programs and postmarketing commitment studies
    • Crafting field-based communication of evidence to external stakeholders by payer type
    • Overcoming evidence barriers through innovative partnership, and developing contract and policy initiatives within your legal and compliance guidelines

    Our blend of experience as developers of economic evidence in the industry—and as academicians and payers—creates a multifaceted approach, generating tightly linked evidence that clearly demonstrates and communicates product value.

  • Evidence synthesis

    From drug development to clinical treatment selection and reimbursement, critical decisions are based on evidence synthesized from multiple sources. Harnessing powerful research techniques, we supply bespoke evidence synthesis studies and analyses appropriate to each life-cycle stage of your product.

    • Systematic literature reviews

      Whether your research questions concern efficacy and safety of interventions, the relationship between end points, the natural course of disease, or the burden of disease, the starting point is the same: a rigorous, systematic literature review to identify, select, and extract data from relevant studies.

    • Meta-analysis

      We use advanced methods to simultaneously analyze multiple interventions, outcomes, and study designs; these combined findings provide deep understanding of the data. Our approach is always forward thinking: Precision Xtract scientists developed many of the processes commonly used in network meta-analysis, including analytic methodology, reporting guidelines (PRISMA), and usage guidelines for policy makers and health care professionals in clinical decision-making (ISPOR Indirect Treatment Comparisons Good Research Practices Task Force).

    • Indirect treatment comparisons, matching adjusted indirect treatment comparisons and network meta-analyses

      Often, payers and decision makers want to compare products for which no direct comparison exists. Our advanced network meta-analyses, including analysis of survival curves, repeated measures analysis, and combination of patient- and study-level data, answer this need. We have supervised hundreds of network meta-analysis studies that included population-adjusted indirect comparisons involving single-arm studies (eg, matched-adjusted indirect comparisons and outcome-regression–based comparisons).

  • Simulation and decision analytic modeling

    Reimbursement decisions often involve trading off competing objectives in the presence of uncertainty about the benefits, harms, and costs of medical interventions. Decision analytic models transparently integrate the available evidence of interventions to evaluate multiple facets of value. Although many such models are developed to substantiate cost-effectiveness claims, they are also powerful tools to evaluate the economic viability of a new pharmaceutical compound—and can therefore support drug development.

    • Decision modeling

      Evidence-based decision analytic models assess risk-benefit, cost-effectiveness, and the public health impact of medical interventions developed according to the latest methodological guidelines and the requirements of HTA and reimbursement bodies.

    • Budget impact analysis

      Population models estimate the financial impact that a new treatment introduces to the payer budget.

  • Real-World evidence generation and evaluation

    Real-world observational research studies can help identify and quantify the value of health care interventions in routine practice settings. They provide insight into the epidemiology, patient and economic burden, and treatment patterns of health conditions—and into the real-world treatment effectiveness, safety, and economic value of medical interventions.

    • Design and analysis of observational studies

      Retrospective observational studies, such as chart reviews, can answer current research questions and guide subsequent prospective observational studies. Our epidemiologists and health economists design and execute these studies, along with cross-sectional surveys on patient outcomes and medical resource use associated with health states.

    • Secondary data analysis

      Analysis of existing subject-level data from administrative claims, electronic health records, pharmacy and lab sources, and disease registries is an efficient means of characterizing disease burden or understanding the real-world value of treatments; leveraging multiple, disparate data sources can help provide even further insights.

  • Craig_White
    Craig White Vice President,
    Managing Director
  • Kathy Lang
    Kathy Lang, PhD Vice President
  • Jeroen_Jansen
    Jeroen Jansen, PhD, MSc Vice President
    & Chief Scientist
  • Phil Cyr, MPH Vice President
  • Health Economics

    Precision Evidence Synthesis Platform (ESP) A comprehensive database of evidence synthesis studies provides insight across disease states, subgroups, interventions, and outcomes.
Learn more about how Precision can help you differentiate your product by quantifying unique sources of value—please visit: PrecisionHealthEconomics.com
Contact us
Discover exactly what Precision can do for you. We look forward to learning about your needs, exploring how we can support you, and sharing our proven approaches. For information and inquiries, please contact:
Zac Stillerman
Zac Stillerman
President and General Manager
phone-icon +1 240.316.3451
Larry Blandford
Larry Blandford, PharmD
Executive Vice President and Managing Partner
phone-icon +1 212.686.2650
J. Bruce Leavitt
J. Bruce Leavitt, MBA
Executive Vice President and Managing Partner
phone-icon +1 203.487.5240
Ross Maclean
Ross Maclean, MD, PHD, MBA
Executive Vice President, General Manager
phone-icon +1 310.984.7708
Harry Grant Schiavi
Harry Grant Schiavi
Managing Partner
phone-icon +1 302.379.1702